Industry News

• New discoveries predict ability to forecast dementia from single molecule  Scientists who recently identified the molecular start of Alzheimer’s disease have used that finding to determine that it should be possible to forecast which type of dementia will develop over time – a form of personalized medicine for neurodegenerative diseases.
  December 11, 2018  
• OncoSec reports data showing single cycle of monotherapy TAVO(TM) improve immune responses  OncoSec announced data that suggests treatment with TAVO(TM) (tavokinogene telseplasmid) has the ability to improve immune responses in heavily pretreated, inoperable and locally advanced TNBC by increasing TIL density, increasing effector cytokines, and upregulating immune-related gene expression.
  December 11, 2018  
• Soligenix to receive $611,000 in non-dilutive funding through NJEDA tax transfer program  Soligenix announced it has received preliminary approval for a tax credit from the New Jersey Economic Development Authority's New Jersey Technology Business Tax Certificate Transfer program. The Company anticipates being able to transfer this credit and receive $611,000 in proceeds by year end.
  December 11, 2018  
• Omeros announces research collaboration with University of Cambridge  Omeros announced a research collaboration with the University of Cambridge, establishing the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR). The OC3IR currently is focusing on research related to OMS721, Omeros’ lead human monoclonal antibody targeting MASP-2.
  December 11, 2018  
• Cambrex expands analytical capabilities at its High Point, NC site  Cambrex announced it is investing $1 million at its High Point, NC site to fit out 1,300 sq. ft. of analytical laboratory space and plans to hire 9 chemical research and development scientists, as well as 6 analytical R&D scientists pursuant to this project.
  December 11, 2018  
• Keryx Biopharmaceuticals stockholders approve merger with Akebia Therapeutics  Keryx Biopharmaceuticals announced that Keryx stockholders voted in favor of adopting the merger agreement among Keryx and inter aliaAkebia Therapeutics. Upon completion of the merger, Keryx stockholders will receive 0.37433 common shares of Akebia for each share of Keryx they own.
  December 11, 2018  
• MyoKardia reports positive data from phase 1b single-ascending dose trial of MYK-491  MyoKardia announced topline results from the Phase 1b single-ascending dose study of MYK-491. MYK-491 was generally well-tolerated and increases in cardiac contractility were observed. MYK-491 is MyoKardia’s most advanced activator molecule designed to increase contractility of the heart.
  December 11, 2018  
• STRATA Skin Sciences secures exclusive license for treating Vitiligo using Excimer laser  STRATA Skin Sciences announced it has reached agreement with an internationally acclaimed health institution regarding U.S. Patents 6,979,327 and 7,261,729 B2 for “Treatment of Vitiligo.” The agreement clarifies STRATA's exclusive license.
  December 11, 2018  
• Neovasc announces positive 12-year follow-up data for Neovasc Reducer™ published in JACC  Neovasc announced the Journal of the American College of Cardiology published new, peer reviewed Reducer data describing the long-term clinical and anatomical follow-up of patients with severe angina pectoris treated with the Neovasc Reducer™ 12 years ago.
  December 11, 2018  
• CHMP extends review period for Portola Pharmaceuticals' OndexxyaTM (andexanet alfa)  Portola announced the Committee for Medicinal Products for Human Use of the EMA has extended the review period for the Company’s marketing authorization application for Ondexxya™ (andexanet alfa). An opinion is now expected by February 28, 2019.
  December 11, 2018  

   (next 10 articles)